Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 1385-1390 | ISSN:2251-6727

Enhancing Research and Development Approaches for FDA Approval of Ophthalmic Products

Namrata Shivde[1], Girish Kashid[2], Shraddha Kundkar[1], Gautham Menon[3], Prashant Patil[4]

1. Department of Regulatory Affairs, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Maharashtra, India-423601.

2. Department of Pharmaceutical Chemistry, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Maharashtra, India-423601.

3. Department of Pharmaceutics, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Maharashtra, India-423601.

4. Department of Pharmaceutics, N.N. Sattha College of Pharmacy, Ahmednagar, Maharashtra, India- 414001.

(Received: 07 January 2024 Revised: 12 February 2024 Accepted: 06 March 2024)

KEYWORDS

FDA, USA, IND, NDA, CDER, Pre-Investigational, Clinical, Non-clinical.

ABSTRACT:

This article offers a detailed overview of the regulatory journey for ophthalmic therapeutic products in the U.S., focusing on safety, efficacy, and quality assurance. It covers pre-investigational New Drug (IND) meetings, Investigational New Drug (IND) applications, clinical and nonclinical development processes, and the intricacies of New Drug Application (NDA) filing. Special attention is given to Emergency Use IND, Investigator-Sponsored IND, and Treatment IND applications. The discussion extends to Biologics License Applications (BLAs) for diverse ocular medications. Emphasis is placed on post-market surveillance in Phase 4 trials, underlining the commitment to continual monitoring of drug safety and efficacy. Pharmaceutical manufacturers navigating the approval process for ophthalmic therapeutics will find this article to be a valuable and insightful resource.

Introduction:

The U.S. Food and Therapeutic Administration (FDA) has established a regulatory pathway for developing ophthalmic therapeutic products. To guarantee topical ophthalmic medication products' safety, efficacy, and general effectiveness in treating eye problems, quality concerns are essential. The United States Pharmacopeia (USP) and additional regulatory bodies offer rules and procedures for the creation, production, and quality assurance of these goods. Products for treating eye conditions are made in several dosage forms, such as gels, ointments, emulsions, suspensions, and implants. This contains sterile dosage forms, which indicate that they have gone through procedures to guarantee the product's sterility, potency, and quality. Any medicine producer seeking approval for their product must first go through the various types of meetings, approval processes & clinical and nonclinical trials.

Pre-IND (Investigational New Drug) Meeting:

Sponsors (businesses or researchers) can ask the FDA for a pre-IND meeting to go over their development plans before to starting formal investigations. During a pre-IND meeting, which also covers other components of the prospective clinical study, the FDA consultation can take place. Requests for such meetings must be made in writing to the relevant FDA reviewing division. An intended agenda, attendance, background details, meeting objectives, and the approximate date that additional documentation will be forwarded to the reviewing division must all be included in the meeting request.(1) A comprehensive information package

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 1385-1390 | ISSN:2251-6727

must be sent to the FDA at least four weeks before the official pre-IND meeting. This meeting's primary goal is to identify preclinical trials that could be supported, as well as potential designations, development, and approval statuses that might enhance or expedite the clinical research or regulatory review process.(2)

Investigational New Drug (IND) Application:

It is necessary to submit an IND application before starting human clinical studies. It is required to notify the FDA as part of the regulatory procedure that a certain drug reagent will be utilized on an experimental basis. An investigational new drug (IND) application is what this notification is known as. The FDA Form 1571 (which covers all applications, primarily those from commercial or research investigators), FDA Form 1572 (which provides information about the safety requirements for specific sections of the FDA from 1571), and FDA Form 3674 (which covers amendments, supplements, and resubmissions under §§ 505, 515, 520 (m), or 510 (k) of the Federal Food, Drug, and Cosmetic Act or § 351 of the Public Health Service Act) are part of the filing process for an IND application. After 30 days of FDA approval, the trial is started(3). The 30-day period is unaffected if the FDA asks for more details or explanation unless they indicate that the study is put on a full or partial clinical hold. A partial hold will permit the starting of one section of the study while prohibiting the start of the other. A clear indication that the trial cannot start is a clinical hold(4).

1. Emergency use IND:
A patient must have an urgent medical need that puts their life in danger. There isn't a widely acknowledged medical substitute for managing the patient. There isn't enough time to ask the IRB for permission to use the investigational product to treat the patient because of the urgent need. a. A doctor or researcher may directly apply to the FDA for an emergency use IND in the rare event that there isn't an open IND. Drug Discovery Technologies 9.10.7 Current Protocols in Pharmacological Supplement 42 The FDA division with the most experience with the investigational product is the recipient of this phone request. While emergency use scenarios may not necessitate IRB permission, each institution maintains its own protocols to guarantee prompt IRB notice of drug use.(5)

2. Investigator-Sponsored IND:
While most multicentre clinical trials are supported by pharmaceutical companies or other research bodies, the bulk of INDs are funded by individual researchers. It's possible that few investigators were obligated to finish and file an IND, even though many enrol in

these clinical trials. The investigator is just needed to participate in these studies; they do not need to decide whether an IND is required or take on the role of IND sponsor.(6)

3. Treatment IND:
While the final clinical work is being completed and the FDA is reviewing the medicine for approval, a Treatment IND application is submitted for the non-emergency use of an investigational treatment that shows promise for serious or immediately life-threatening disorders. Under a therapy IND, a large number of patients may be treated (21 CFR 312.35).
The next step in the approval process is non clinical trials and clinical trials.(7)

IND Applications for Clinical Investigation (***Product Development***)	**IND Application Reporting**	**IND Application Procedures**	**IND Applications for Clinical Treatment** (***Expanded Access***)
Overview	Overview	Overview	Overview
Content & Format	Amendments to Protocols	IND exemptions Conditions	Content & Format
Administrative and Regulatory Aspects	Informational Updates	Interaction with FDA	Emergency IND Timeline (Single Patient Care in an Emergency Situation)

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 1385-1390 | ISSN:2251-6727

Non clinical Aspects	Report on Safety	Clinical Decision on Hold	For Physicians: A guide to Non-emergency Submissions for Expanded Access for a Single Patient
Clinical Components	Annual Report	Investigator's Obligations	Treatment for Large Patient Population

Table: Investigators about submitting Investigational New Drug (IND) applications to FDA

Non-Clinical Development:

Good laboratory practice (GLP) must be followed when doing nonclinical investigations like safety pharmacology and general toxicology that are meant to bolster the safety of clinical trials. GLP does not mandate the conduct of primary pharmacology or pharmacokinetic (PK) research, such as absorption, distribution, metabolism, and excretion (ADME) studies. Nonetheless, it is typical for PK and ADME investigations to be carried out in compliance with GLP guidelines. Various species' ocular anatomy is taken into account in toxicological research, which could influence the choice of species. Ocular toxicity studies are typically carried out in nonrodents (dogs, pigs, rabbits, monkeys, and so on) because of factors like eye size and other anatomical concerns. The nonclinical study categories that are generally required to support drug development are outlined in the ICH M3(R2) guidance document, along with the appropriate timing for these studies during the development process.(8)
The overall amount of drug-derived material that passes through the gastrointestinal epithelium is referred to as absorption, while the amount of biologically active material that enters the systemic circulation is referred to as bioavailability. The length of a drug's effect is frequently determined by how quickly the body gets rid of the active ingredients, either by binding to and transporting the drug away from the physiologically active sites and excreting it from the body, or by chemically changing (metabolizing) the substance with the help of drug-metabolizing enzymes.(9)

Clinical development:

Determining the indication, dosage range, and schedule at which a medication is both safe and effective for a given usage in a patient population is the main objective of the clinical development process for new drugs. The clinical development plan (CDP) outlines an orderly program of clinical studies, each with distinct goals in order to meet these requirements. Small, short-term trials are used in the early stages of clinical research to gather data on pharmacodynamics, pharmacokinetics, safety, and tolerability. This information is then used to determine the ideal dosage range and delivery schedule for the first round of exploratory therapeutic trials. Subsequently, an increased number of patients participate in larger, more conclusive confirmatory investigations.(10)

Clinical trial can be divided into 4 phases which includes

Phase 1: In order to develop a preliminary safe and effective drug administration program that serves as a roadmap for the subsequent phase of clinical trials, the tolerance of participants to novel medications is examined. In vivo studies are conducted on medication pharmacokinetics, including distribution, excretion, metabolism, absorption, and another pharmacokinetics. A well-designed program and protocol can ensure a clinical trial of the highest standard and facilitate the smooth conduct of the study.(11)

Phase 2: Phase II studies provide a convincing description of the disease benefit of treatment and assess possible efficacy. It is not assumed that the intervention will have any kind of therapeutic impact. These larger-scale (100–300 individuals) studies are intended to evaluate the efficacy of the medication and to carry out ongoing safety evaluations. The two phases of Phase II are called Phase IIA and Phase IIB. Phase IIA trials are pilot studies that assess safety and efficacy in specific populations with a condition or disease that needs to be treated, diagnosed, or prevented; the objectives of these trials may include dose-response, patient type, frequency of dosage, or other indicators of safety and efficacy. During this Phase II, the drug's development process typically fails

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 1385-1390 | ISSN:2251-6727

when it is shown to not function as intended or to have harmful side effects.(12)

Phase 3: A phase III study must clearly identify the hypotheses it is testing prior to its initiation in order to be considered confirmatory. Sample sizes are usually selected to assess the treatment effect with high statistical precision and to have a high likelihood of eliminating out the possibility of ineffective therapy. Because the phase III study's greater sample numbers provide a better potential to uncover relatively infrequent significant toxicities, the collection of safety data remains crucial. Typically, the approval procedure does not require statistically demonstrated higher rates of toxicities before cautioning patients and physicians. Anecdotal evidence of unanticipated, extremely serious side outcomes will frequently require additional research on a suggested treatment, depending on the condition and patient population.(13)

NDA filling:

A new drug application (NDA) can only be submitted if the medication passes all three stages of clinical trailing and contains all data about humans and animals, data analysis, the pharmacokinetics of the medication and its production, and appropriate labelling. A group of scientists analyses the preclinical, clinical reports, and risk-benefit analysis (a product's potential benefits outweigh its possible harmful effects) at the Centre for Drug Evaluation and Research. A new drug's producer files a New Drug Application (NDA), which is essentially a request to manufacture and sell the drug in the United States if clinical trials verify that the drug is reasonably safe, and effective, and won't put patients at undue risk.(14) Manufacturers can submit one of two types of NDAs, which are titled after their respective locations in the FFDCA.

- An application that includes complete results on safety and effectiveness investigations carried out by the applicant, for the applicant, or for which the applicant has the right of reference or use is known as a 505(b)(1) NDA.
- An application that meets the requirements for approval under 505(b)(2) NDAs includes comprehensive reports of safety and effectiveness investigations, at least some of which are derived from studies that the applicant did not conduct or for which the applicant does not have a right of reference or use (e.g., published research, the FDA's finding of safety and/or efficiency for a listed drug).

CDER authorities examine the drug's safety and efficacy data, examine samples, survey the manufacturing facilities for the final product, and verify the accuracy of the proposed labelling during the NDA review process.(15)

Fundamentals of NDA Submission:

NDAs may have up to 15 distinct parts, as specified in Form FDA-356h, Application to Market a New Drug for Human Use or As an Antibiotic Drug for Human Use:

1) Index
2) Summary
3) Chemistry, Manufacturing, and Control;
4) Samples, Method Validation Package, and Labeling
5) Nonclinical Pharmacology and Toxicology
6) Human Pharmacokinetics and Bioavailability
7) Microbiology (for anti-microbial drugs only);
8) Clinical Data;
9) Safety Update Report (typically submitted 120 days after the NDA's submission);
10) Statistical;
11) Case Report Tabulations;
12) Case Report Forms;
13) Patent Information;
14) Patent Certification; and
15) Other Information.(16)

General Requirements for Filling of NDA

The application must be submitted in two copies per the updated NDA regulations:
A: copy from the archives (It is a permanent record of the application submission)
B: Review copy
Six technical sections make up this section:

1) Controls, Manufacturing, and Chemistry (CMC).
2) Toxicology and nonclinical pharmacology.
3) Human Bioavailability and Pharmacokinetics.
4) microbiology, if necessary.
5) clinical information.
6) statistical.

To allow the FDA to take action within 180 days of receiving the NDA, the CDER stamps the document with a reception date known as the Review Clock under Review Time Frames (21CFR 314.100). The

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 1385-1390 | ISSN:2251-6727

application is assigned for examination by the FDA.(17)

BLA submission:

Applicants for BLAs must provide Form FDA 356h to CBER. The application is submitted in eCTD or paper format. Pre-clinical and clinical data, manufacturing site details, label drafts, validation standards for key procedures, case studies, and other relevant information should all be included.(18) The FDA's Biologics License Application (BLA) process varies based on the kind and origin of the medication. Certain ocular medications, such as gene therapies or monoclonal antibodies, can fit under this category and require a BLA to be submitted. Alternative ophthalmic medications, including biosimilars or small molecule medications, might require the submission of an Abbreviated New Drug Application (ANDA) or New Drug Application (NDA). Ophthalmic medications must adhere to the FDA's guidance papers and meet the quality criteria and specifications for sterile pharmaceutical goods, regardless of the type of application.(19)

Phase 4: (Post Market Surveillance)

After a medicine is approved, phase IV trials are frequently performed to study drug safety. But nothing is known about the features of modern phase IV clinical trials or if the quality of these investigations is high enough to improve medical understanding of pharmacovigilance. Determine the essential features of phase IV clinical trials that used the Clinical Trials to assess drug safety.(20)
Phase IV research is becoming more and more popular. It includes implementation research, which looks into improved ways to guarantee the successful delivery of an intervention, and post-marketing surveillance, which monitors the impact of interventions (such as how to expand the coverage of a vaccination programme). A common objective of Phase IV studies is to offer proof that the health intervention can be safely and successfully incorporated into clinical or public health practice, where "successful" refers to not only that it is possible to do so, but also that the treatment is still effective and that implementing it has no major adverse impacts.(21)

Conclusion:

This article provides a thorough and insightful exploration of the regulatory pathway for ophthalmic therapeutic products in the United States. It underscores the paramount importance of safety, efficacy, and quality assurance in the development of topical ophthalmic medications. By detailing the intricate processes involved in pre-IND meetings, Investigational New Drug (IND) applications, nonclinical development, and the various phases of clinical trials, the article offers a valuable resource for pharmaceutical manufacturers seeking approval for their products. The comprehensive overview of the New Drug Application (NDA) filing, including the nuanced differences between 505(b)(1) and 505(b)(2) types, sheds light on the meticulous review conducted by the Centre for Drug Evaluation and Research (CDER). The discussion on Biologics License Applications (BLAs) provides additional clarity, considering the diverse nature of ocular medications. Furthermore, the emphasis on post-market surveillance in Phase 4 trials reinforces the commitment to ongoing monitoring and evaluation of drug safety and effectiveness after approval.

References

1. Woodbury-Harris K, Coull B. Clinical Trials in the Neurosciences [Internet]. Cerebrovasc Dis. Karger; 2012 [cited 2024 Jan 24]. 213 p. Available from: http://www.karger.com/Article/Abstract/337009

2. Learn about Pre-IND Meetings - Toolkit [Internet]. [cited 2024 Jan 24]. Available from: https://toolkit.ncats.nih.gov/module/prepare-for-clinical-trials/participating-in-initial-meetings-with-regulators/learn-about-pre-ind-meetings/

3. Kumari P, Thakur A, Goldar E, Chatterjee A, Chatterjee S, Kumar R, et al. ARTICLE INFO ABSTRACT Article history press as Abhimanyu Thakur et al. Regulatory Requirements For Filing An Investigational New Drug Application With FDA. Indo Am J Pharm Res [Internet]. 2015 [cited 2024 Jan 24];2015(02):5. Available from: www.iajpr.comwww.iajpr.com

4. Holbein MEB. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators [Internet]. Vol. 57, Journal of Investigative Medicine. SAGE PublicationsSage CA: Los Angeles, CA; 2009 [cited 2024 Jan 24]. p. 688–94. Available

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 1385-1390 | ISSN:2251-6727

from: https://journals.sagepub.com/doi/abs/10.2310/JIM.0b013e3181afdb26

5. Ferkany JW, Williams M. The IND application. Curr Protoc Pharmacol. 2008;(SUPPL. 42):1–23.

6. Haakenson C, Fye CL, Sather MR, Toussaint DJ. The investigator-sponsored IND in clinical trials. Control Clin Trials. 1987;8(2):101–9.

7. Rita Misra R, Ramineni B. Requirements for filing an investigational new drug application [Internet]. Vol. 262, Novel Designs of Early Phase Trials for Cancer Therapeutics. Elsevier Inc.; 2018. 7–16 p. Available from: http://dx.doi.org/10.1016/B978-0-12-812512-0.00002-6

8. Weir AB, Wilson SD. Nonclinical Regulatory Aspects for Ophthalmic Drugs. In: Molecular and Integrative Toxicology. 2013. p. 259–94.

9. Song NN, Zhang S yu, Liu C xiao. Overview of factors affecting oral drug absorption. Asian J Drug Metab Pharmacokinet [Internet]. 2004;4(3):167–76. Available from: http://www.hktmc.com/ChineseMedia/Magazine/Medicine/ajdmpk/AJDMPK-2004-3/asian2004-3(167-176).pdf

10. Singh G. Target Product Profile and Clinical Development Plan [Internet]. Pharmaceutical Medicine and Translational Clinical Research. Elsevier Inc.; 2017. 65–80 p. Available from: http://dx.doi.org/10.1016/B978-0-12-802103-3.00005-5

11. Wei Y, Li H, Wang H, Zhang S, Sun Y. Psychological status of volunteers in a phase I clinical trial assessed by symptom checklist 90 (SCL-90) and eysenck personality questionnaire (EPQ). Med Sci Monit. 2018;24:4968–73.

12. Mahan VL. Clinical Trial Phases. Int J Clin Med. 2014;05(21):1374–83.

13. Trials NRC (US) P on HMD in C. Clinical Trials: Overview and Terminology. 2010 [cited 2024 Jan 24]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK209903/

14. Jawahar N, Vidhya Lakshmi T. Regulatory requirements for the drug approval process in US, Europe and india. J Pharm Sci Res. 2017;9(10):1943–52.

15. Thaul S, Dabrowska A. How FDA approves drugs and regulates their safety and effectiveness. FDA Drug Approv Elem Considerations. 2018;1–28.

16. FDA. Ind , Nda , Anda , Concept of Para I To Iv , Exclusivity : Content , Format & Application. 1938;

17. US Food and Drug Administration. 21 CFR § 314.50 - Content and format of an NDA [Internet]. 2020 [cited 2024 Jan 24]. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314.50

18. Adminstration USF and D. Biologics License Applications (BLA) Process. Biol Licens Appl Process [Internet]. 2015 [cited 2024 Jan 24];1–2. Available from: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber

19. FDA. Original NDA and Original BLA Approvals [Internet]. 2020 [cited 2024 Jan 24]. Available from: https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/nda-and-bla-approvals

20. Zhang X, Zhang Y, Ye X, Guo X, Zhang T, He J. Vol. 6, BMJ Open. 2016. p. 1–9 Overview of phase IV clinical trials for postmarket drug safety surveillance: A status report from the ClinicalTrials.gov registry.

21. Phase IV studies - Field Trials of Health Interventions - NCBI Bookshelf [Internet]. [cited 2024 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305508/